Shanghai Henlius Biotech stock | Price target for 2026, price & analyst rating

Shanghai Henlius Bio...

SEHK:2696

HK$ 71,70

+ HK$5,70 (8,64%)

71,70 HK$

+HK$5,70 (8,64%)

End-of-day quote: 03/27/2026

Shanghai Henlius Biotech Stock Value

The analyst rating for SEHK:2696 is currently Buy.

Buy

Shanghai Henlius Biotech Company Info

EPS Growth 5Y

23,86%

Market Cap

HK$35,87 B

Long-Term Debt

HK$1,01 B

Quarterly earnings

05/27/2026 (E)

Dividend

HK$0,00

Dividend Yield

0,00%

Founded

2010

Industry

Health Care

Country

China

Website

Shanghai Henlius Biotech

ISIN Number

CNE100003N76

Website

http://www.henlius.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

HK$102,47

42.91%

Last Update: 03/26/2026

Analysts: 7

Highest Price Target HK$134,69

Average Price Target HK$102,47

Lowest Price Target HK$94,59

In the last five quarters, Shanghai Henlius Biotech’s Price Target has risen from HK$2,75 to HK$14,18 - a 415,64% increase. Seven analysts predict that Shanghai Henlius Biotech’s share price will increase in the coming year, reaching HK$102,47. This would represent an increase of 42,91%.

Top growth stocks in the health care sector (5Y.)

What does Shanghai Henlius Biotech do?

Shanghai Henlius Biotech, Inc. engages in the research and development (R&D), production, and sale of monoclonal antibody (mAb) therapies. In addition to therapeutic development, the company offers various related technical services, excluding the development and application of human stem cells and genetic diagnosis or therapy technologies. Business Segments The company operates primarily within a singular reportable segment, which encompasses biopharmaceutical research and development, manuf...

Shanghai Henlius Biotech, Inc. engages in the research and development (R&D), production, and sale of monoclonal antibody (mAb) therapies.

In addition to therapeutic development, the company offers various related technical services, excluding the development and application of human stem cells and genetic diagnosis or therapy technologies.

Business Segments

The company operates primarily within a singular reportable segment, which encompasses biopharmaceutical research and development, manufacturing, and sales.

The biopharmaceutical segment is directed toward creating innovative therapies, specifically monoclonal antibodies, that target various therapeutic areas. The company's clinical pipeline includes a variety of monoclonal antibodies at different development stages ranging from preclinical research to late-stage clinical trials-indicating a proactive approach to drug development and market introduction.

In manufacturing, the company utilizes its facilities to produce mAbs under strict compliance with Good Manufacturing Practice (GMP) standards. This commitment to quality is crucial, especially given the regulatory scrutiny associated with biopharmaceutical products. The manufacturing capabilities also facilitate large-scale production, which is essential for fulfilling both domestic and global market needs, further enhancing the company's position in the industry.

Sales operations are structured around strategic marketing to various healthcare providers and institutions, ensuring broad access to its innovative therapies. The company's marketing efforts are supported by its robust clinical data and the established efficacy of its mAb products, enhancing its appeal to both healthcare providers and patients.

Furthermore, the company also focuses on establishing partnerships and collaborations with other biopharmaceutical companies, academic institutions, and research organizations. These partnerships can accelerate the development timeline of new therapies and broaden its innovative capabilities.

Business Strategy

The company employs a multi-faceted business strategy focuses on differentiation through innovation, strategic partnerships, and market expansion. The company is primarily dedicated to advancing its R&D capabilities, with a clear focus on developing next-generation biopharmaceutical products that meet unmet medical needs. The emphasis on innovation is evident through the company's substantial investments in research, signifying its commitment to staying at the forefront of biopharmaceutical advancements.

One of the key strategic components of the company's business model is its pipeline development driven by robust scientific research. The company prioritizes developing monoclonal antibody therapies through extensive preclinical and clinical trials. By following stringent clinical protocols and leveraging novel technologies, the company aims to create effective treatments for various diseases, notably cancer and autoimmune disorders.

In addition to building its pipeline, the company actively seeks collaborations with global pharmaceutical companies and academic institutions. These partnerships enhance the company's technical capabilities and expedite the development process by sharing knowledge, resources, and expertise.

Market expansion serves as another cornerstone of the company's strategy. The company looks to diversify its geographical footprint, ensuring that its innovative therapies are accessible in various regions. The company is focuses on expanding its presence across Asia, North America, Europe, and other emerging markets to tap into diverse customer bases and capitalize on varying healthcare demands.

Furthermore, the commitment to maintaining high-quality standards in production processes underpins the company's strategic objectives. By investing in state-of-the-art manufacturing facilities, the company ensures it can produce high-quality biopharmaceuticals that comply with stringent regulatory requirements.

Products and Services

The company offers an extensive range of products and services that primarily focus on biopharmaceutical development, with a specialization in monoclonal antibodies. The company's product portfolio comprises multiple monoclonal antibody candidates targeting various therapeutic indications, including oncology, autoimmune diseases, and other critical health issues.

The monoclonal antibodies developed by the company are designed for specific targeting and therapeutic functions. Examples include mAb treatments for different types of cancers, which have shown promising results in enhancing patient outcomes and survival rates. Additionally, the company is involved in developing biosimilars, which can provide cost-effective alternatives to existing medications while maintaining efficacy and safety.

In conjunction with its therapeutic offerings, the company provides comprehensive research and development services. This includes preclinical research, clinical trial management, regulatory consulting, and technical support related to the development of biopharmaceuticals.

The company also emphasizes technical consultation and technology transfer services, aimed at aiding partners and collaborators in navigating complex biopharmaceutical development processes. This includes sharing its expertise on monoclonal antibody development methodologies, ensuring that the technology can be leveraged for innovative product creation in various settings.

In the manufacturing domain, the company operates advanced biomanufacturing facilities capable of producing high-quality mAbs at scale.

Geographical Markets Served

The company serves various geographical markets, which include the Chinese Mainland, the Asia Pacific (excluding Chinese Mainland), North America, South America, and Europe. A significant portion of the company's revenue is generated from the Chinese Mainland, indicative of a strong market presence and acceptance of its products within domestic healthcare systems.

The company reports consistent growth in international markets as well, particularly in North America and Europe, where it has been expanding its outreach through strategic marketing initiatives and compliance with local regulatory frameworks. Efforts to penetrate the Asia-Pacific region further exemplify the company's focus on geographical expansion, aiming to establish a competitive foothold in emerging markets with rising healthcare demands.

Customers

The company serves a diverse range of customers across various sectors of the healthcare industry. The company's client base includes hospitals, healthcare providers, and research institutions, which rely on its innovative biopharmaceutical products and services to meet patient needs.

Within the healthcare ecosystem, pharmaceutical companies often collaborate as partners in development projects, taking advantage of the company's expertise in monoclonal antibody therapeutics. The business solution model provides these partners with access to advanced technology and operational capabilities.

The structure of the industry suggests that major pharmaceutical firms or healthcare providers are included among the primary clientele.

Marketing and Distribution Channels

The company adopts a multi-channel approach for marketing and distribution to ensure that its innovative biopharmaceutical products reach diverse markets effectively. The company's marketing strategies are complemented by strong emphasis on building relationships with healthcare providers, hospitals, and key opinion leaders within the medical community.

The marketing initiatives encompass a thorough understanding of market dynamics and patient needs. The company invests in educational outreach, disseminating critical information about its products through conferences, scientific literature, and direct engagement with healthcare professionals. This educational component plays a crucial role in facilitating informed choices among providers and enhancing the adoption of its innovative therapies.

In terms of distribution, the company relies on a combination of direct sales and partnerships with distributors and healthcare organizations. This dual channel approach allows flexibility in accommodating various market needs while ensuring that the products are available in a timely manner to healthcare providers and patients alike.

The company's commitment to customer engagement extends to after-sales support, wherein feedback mechanisms are established to address any concerns and continually improve service delivery.

Government Regulations

Regulatory authorities, such as the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA) in North America, enforce comprehensive guidelines regarding clinical trials, product safety, efficacy, and post-market surveillance. The company actively collaborates with these regulatory bodies to ensure all processes align with legal mandates, thereby facilitating timely approvals for its therapeutic products.

History

Shanghai Henlius Biotech, Inc. was founded in 2010.

Shanghai Henlius Biotech Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by sectors:** - **Biopharmaceuticals:** 70% - **Oncology:** 20% - **Autoimmune diseases:** 10% **TOP 3 markets and their percentage shares:** - **China:** 60% - **Europe:** 25% - **Latin America:** 15% Shanghai Henlius Biotech, Inc. generates the majority of its revenue from...

At which locations are the company’s products manufactured?

**Production Sites:** - **Shanghai, China** - **Taiwan, China** Shanghai Henlius Biotech, Inc. mainly produces its biopharmaceutical products in Shanghai, China. The company has modern production facilities there that are specialized in the manufacturing of biosimilars and innovative biological dru...

What strategy does Shanghai Henlius Biotech pursue for future growth?

**Focus on Biosimilars:** Shanghai Henlius Biotech, Inc. specializes in the development and commercialization of biosimilars. **Pipeline Expansion:** The company plans to expand its product pipeline by introducing new biosimilars and innovative biologics. **International Expansion:** Henlius aims...

Which raw materials are imported and from which countries?

**Main raw materials:** Biopharmaceutical active ingredients, cell cultures, reagents **Countries of origin:** USA, Germany, Switzerland Shanghai Henlius Biotech, Inc. is a biopharmaceutical company specializing in the development and manufacturing of biosimilars and innovative biological drugs. F...

How strong is the company’s competitive advantage?

**Market share in the Biosimilar segment:** 8% (2024) **R&D investments:** 1.2 billion USD (2024) **Number of approved Biosimilars:** 5 (2025) Shanghai Henlius Biotech, Inc. has established itself as a significant player in the field of Biosimilars. With a market share of 8% in 2024, the co...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** Estimated at 45% (2025) **Insider Purchases/Sales:** No significant transactions reported in the last year The institutional investor share in Shanghai Henlius Biotech, Inc. is estimated to be around 45%, indicating a strong confidence from institutional investors...

What percentage market share does Shanghai Henlius Biotech have?

**Market share of Shanghai Henlius Biotech, Inc.:** 3.5% (2025, estimated) **Top competitors and their market shares:** 1. **Roche Holding AG:** 15% 2. **Amgen Inc.:** 12% 3. **Novartis AG:** 10% 4. **Merck & Co., Inc.:** 9% 5. **Pfizer Inc.:** 8% 6. **Bristol-Myers Squibb Company:** 7% 7. **Sa...

Is Shanghai Henlius Biotech stock currently a good investment?

**Revenue Growth:** 18% (2024) **R&D Expenses:** 25% of revenue (2024) **Product Pipeline:** 25 projects in various stages of development (2025) Shanghai Henlius Biotech, Inc. achieved a revenue growth of 18% in 2024, attributed to a strong product pipeline and successful market launches. T...

Does Shanghai Henlius Biotech pay a dividend – and how reliable is the payout?

**Dividend payment:** No dividend (as of 2025) Shanghai Henlius Biotech, Inc. has not distributed any dividends to its shareholders so far. The company is heavily involved in biopharmaceutical research and development, which typically requires high investments. In the biotechnology industry, it is...

New support ticket

Explore

Shanghai Henlius Biotech Stock Value

Shanghai Henlius Biotech Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Shanghai Henlius Biotech do?

Shanghai Henlius Biotech Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Shanghai Henlius Biotech Stock Value

Shanghai Henlius Biotech Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Shanghai Henlius Biotech do?

Shanghai Henlius Biotech Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.